AnaptysBio (NASDAQ:ANAB) Price Target Lowered to $52.00 at HC Wainwright

AnaptysBio (NASDAQ:ANAB) had its target price cut by HC Wainwright from $55.00 to $52.00 in a research note released on Wednesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other research firms also recently commented on ANAB. Guggenheim lifted their target price on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. UBS Group increased their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Truist Financial boosted their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Finally, Wedbush reaffirmed an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and an average price target of $55.45.

AnaptysBio Trading Up 11.7 %

AnaptysBio stock opened at $22.21 on Wednesday. The company has a 50-day moving average price of $33.30 and a 200 day moving average price of $29.89. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31. The stock has a market cap of $609.31 million, a P/E ratio of -3.50 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. As a group, analysts forecast that AnaptysBio will post -6.84 EPS for the current year.

Insiders Place Their Bets

In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now directly owns 15,398 shares in the company, valued at approximately $595,440.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the stock in a transaction on Wednesday, August 14th. The stock was bought at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the acquisition, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock worth $892,936 over the last 90 days. Corporate insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently modified their holdings of ANAB. Frazier Life Sciences Management L.P. raised its stake in AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after buying an additional 1,265,891 shares in the last quarter. StemPoint Capital LP increased its holdings in shares of AnaptysBio by 499.0% in the 1st quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock valued at $6,070,000 after acquiring an additional 224,548 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the last quarter. Finally, Platinum Investment Management Ltd. acquired a new position in AnaptysBio in the first quarter valued at approximately $1,490,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.